Results 171 to 180 of about 24,930 (235)

Circular economy assessment of biomethane value chain in Brazil

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract From the numerous opportunities to add value to biomass in Brazil, biomethane production in sugarcane mills presents significant potential. This study introduces a diagnostic framework grounded in circular economy (CE) principles to assess new biomethane projects, aligning with the strategic objectives of product diversification, full biomass ...
Luciana Fonseca Moreira   +3 more
wiley   +1 more source

From economic visions to healthier nations: the role of Gulf Cooperation Council countries national development visions in shaping noncommunicable disease policies. [PDF]

open access: yesFront Public Health
Alfawaz R   +10 more
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova   +5 more
wiley   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner   +5 more
wiley   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić   +4 more
wiley   +1 more source

From evidence to action: expert perspectives on stakeholder dialogues in Swiss health policy. [PDF]

open access: yesInt J Public Health
Rubinelli S   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy